Fiera Capital Corp Has $73.69 Million Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Key Points

• Fiera Capital Corp reduced its stake in Thermo Fisher Scientific by 4.8%, now holding 148,086 shares valued at approximately $73.7 million.
• Thermo Fisher announced a quarterly dividend of $0.43 per share, with a payout ratio of 9.95%, indicating a consistent return to shareholders.
• Wall Street analysts have a "Moderate Buy" average rating for Thermo Fisher, with an average price target set at $593.00.

Fiera Capital Corp lessened its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 4.8% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 148,086 shares of the medical research company's stock after selling 7,466 shares during the quarter. Fiera Capital Corp's holdings in Thermo Fisher Scientific were worth $73,688,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of TMO. Cypress Advisory Group LLC acquired a new stake in Thermo Fisher Scientific during the 4th quarter valued at $253,000. GAMMA Investing LLC increased its stake in shares of Thermo Fisher Scientific by 22.0% in the 1st quarter. GAMMA Investing LLC now owns 4,862 shares of the medical research company's stock valued at $2,419,000 after buying an additional 877 shares during the period. Deutsche Bank AG increased its stake in shares of Thermo Fisher Scientific by 9.5% in the 4th quarter. Deutsche Bank AG now owns 1,321,633 shares of the medical research company's stock valued at $687,553,000 after buying an additional 114,277 shares during the period. Hancock Whitney Corp increased its stake in shares of Thermo Fisher Scientific by 0.6% in the 4th quarter. Hancock Whitney Corp now owns 5,386 shares of the medical research company's stock valued at $2,802,000 after buying an additional 30 shares during the period. Finally, Cetera Trust Company N.A increased its stake in shares of Thermo Fisher Scientific by 3.3% in the 1st quarter. Cetera Trust Company N.A now owns 4,646 shares of the medical research company's stock valued at $2,312,000 after buying an additional 150 shares during the period. Institutional investors own 89.23% of the company's stock.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of the company's stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the sale, the executive vice president owned 22,367 shares in the company, valued at $10,735,712.66. This represents a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Stock Down 1.0%

TMO traded down $4.67 on Friday, hitting $463.01. 1,814,800 shares of the company were exchanged, compared to its average volume of 2,525,038. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $627.88. The company has a market cap of $174.78 billion, a PE ratio of 26.74, a PEG ratio of 2.55 and a beta of 0.77. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. The stock's fifty day moving average is $419.50 and its 200-day moving average is $468.31.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%. The business had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. During the same quarter in the prior year, the company posted $5.37 earnings per share. Thermo Fisher Scientific's revenue was up 2.9% on a year-over-year basis. Equities research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be paid a $0.43 dividend. The ex-dividend date is Monday, September 15th. This represents a $1.72 annualized dividend and a yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio is currently 9.95%.

Analyst Upgrades and Downgrades

TMO has been the subject of several research reports. Argus lowered their target price on Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating for the company in a research note on Tuesday, April 29th. Stifel Nicolaus lowered their target price on Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating for the company in a research note on Thursday, April 24th. The Goldman Sachs Group set a $610.00 price objective on Thermo Fisher Scientific and gave the stock a "buy" rating in a research note on Wednesday, April 23rd. Raymond James Financial reaffirmed an "outperform" rating and set a $535.00 price objective (up from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Finally, HSBC reaffirmed a "hold" rating and set a $510.00 price objective on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Six investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, Thermo Fisher Scientific has an average rating of "Moderate Buy" and a consensus price target of $593.00.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.